Last reviewed · How we verify

RNTCP Category I treatment for 9months

All India Institute of Medical Sciences · Phase 3 active Small molecule

RNTCP Category I treatment for 9months is a Antitubercular Small molecule drug developed by All India Institute of Medical Sciences. It is currently in Phase 3 development for Pulmonary tuberculosis, Extrapulmonary tuberculosis.

Isoniazid is a prodrug that is converted to its active form, which inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis.

Isoniazid is a prodrug that is converted to its active form, which inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis. Used for Pulmonary tuberculosis, Extrapulmonary tuberculosis.

At a glance

Generic nameRNTCP Category I treatment for 9months
SponsorAll India Institute of Medical Sciences
Drug classAntitubercular
TargetInhA (Isoniazid target)
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

This inhibition disrupts the cell wall formation of the bacteria, ultimately leading to cell death. Isoniazid is a key component of the RNTCP Category I treatment regimen for tuberculosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RNTCP Category I treatment for 9months

What is RNTCP Category I treatment for 9months?

RNTCP Category I treatment for 9months is a Antitubercular drug developed by All India Institute of Medical Sciences, indicated for Pulmonary tuberculosis, Extrapulmonary tuberculosis.

How does RNTCP Category I treatment for 9months work?

Isoniazid is a prodrug that is converted to its active form, which inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis.

What is RNTCP Category I treatment for 9months used for?

RNTCP Category I treatment for 9months is indicated for Pulmonary tuberculosis, Extrapulmonary tuberculosis.

Who makes RNTCP Category I treatment for 9months?

RNTCP Category I treatment for 9months is developed by All India Institute of Medical Sciences (see full All India Institute of Medical Sciences pipeline at /company/all-india-institute-of-medical-sciences).

What drug class is RNTCP Category I treatment for 9months in?

RNTCP Category I treatment for 9months belongs to the Antitubercular class. See all Antitubercular drugs at /class/antitubercular.

What development phase is RNTCP Category I treatment for 9months in?

RNTCP Category I treatment for 9months is in Phase 3.

What are the side effects of RNTCP Category I treatment for 9months?

Common side effects of RNTCP Category I treatment for 9months include Peripheral neuropathy, Hepatitis, Rash.

What does RNTCP Category I treatment for 9months target?

RNTCP Category I treatment for 9months targets InhA (Isoniazid target) and is a Antitubercular.

Related